Related Experiment Video

Updated: Jul 5, 2026

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates
09:47

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates

Published on: May 10, 2022

Targeting proteasomes as therapy in multiple myeloma

Dharminder Chauhan1, Teru Hideshima, Kenneth C Anderson

  • 1Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

Advances in Experimental Medicine and Biology
|April 29, 2008
PubMed

Insights

The Ubiquitin-proteasome pathway (UPP) is crucial for cell functions. Bortezomib (Velcade) targets UPP to treat multiple myeloma by inducing cancer cell death.

Area of Science:

  • Molecular Biology
  • Oncology
  • Pharmacology

Background:

  • The Ubiquitin-proteasome pathway (UPP) governs intracellular protein degradation, impacting vital cellular processes like cell cycle, inflammation, transcription, DNA replication, and apoptosis.
  • Proteasome inhibitor Bortezomib (Velcade) is a validated therapeutic agent for relapsed/refractory multiple myeloma (MM).

Purpose of the Study:

  • To elucidate the molecular mechanisms underlying Bortezomib-induced cytotoxicity in multiple myeloma.
  • To identify molecular targets associated with Bortezomib sensitivity and resistance.
  • To inform the development of novel therapies and combination strategies for multiple myeloma.

Main Methods:

  • Oligonucleotide microarrays were employed to analyze gene expression profiles.
  • Proteomic studies were conducted to investigate protein-level changes.
  • These methods collectively aimed to delineate the molecular pathways affected by Bortezomib.

Main Results:

  • The study is actively delineating the molecular mechanisms of Bortezomib's action.
  • Key targets influencing sensitivity and resistance to Bortezomib are being defined.
  • Insights into Bortezomib's effects are paving the way for next-generation treatments.

Conclusions:

  • Understanding Bortezomib's molecular targets is essential for optimizing multiple myeloma therapy.
  • This research supports the rationale for developing combination therapies to enhance treatment efficacy.
  • Further investigation into UPP modulation holds promise for future cancer treatments.

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
The Proteasome01:13

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
The Proteasome Structure01:17

The Proteasome Structure

The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...